CERo Therapeutics(OTC) CERO

CERo develops cell therapies to help the immune system fight cancer. Its main products aim to treat blood cancers and solid tumors. These therapies are designed for patients with few other treatment options.

Lab Bench to Bedside: CERo’s Product Lineup

• Engineered T cell therapies: Custom immune cells designed to target and destroy cancer cells; 0% of revenue (pre-commercial).
• CER-1236 (lead candidate): In early clinical trials for acute myelogenous leukemia, a type of blood cancer; 0% of revenue.
• Pipeline therapies: Investigational treatments for lung and ovarian cancers; 0% of revenue.

Growth Spurts and Strategic Moves

• Launched first clinical trial for CER-1236 in May 2025.
• Received U.S. FDA orphan drug status for CER-1236 in July 2025.
• Filed and cleared new drug applications for lung and ovarian cancer therapies in March 2025.
• Raised capital through multiple private placements and equity lines in 2024 and 2025.
• Completed two reverse stock splits in January and June 2025 to maintain Nasdaq listing.

Why CERo Is a Bit Different

CERo combines features of both major immune system branches in its therapies, aiming for broader cancer targeting. The company’s platform is designed to address cancers that resist standard treatments. Its small team focuses on early-stage research and regulatory progress.

Five Things You Need to Know

• No revenue reported for Q2 2025 or prior periods (pre-commercial).
• Net loss was $5.4 million in Q2 2025, increasing 121.2% from a net loss of $2.4 million in Q2 2024.
• Cash position was $3.3 million as of June 30, 2025.
• Operating cash outflow was $9.07 million for the first half of 2025.
• Company has eight full-time employees and relies on external funding.

Bottom Line

CERo remains an early-stage biotech focused on developing new cancer therapies. The company’s future depends on clinical progress and continued access to funding.